Mar 10 2025 1 mins
As of the latest available data, Pfizer's stock price is approximately twenty-six dollars and twenty-four cents per share. The trading volume has been fluctuating, with recent days showing volumes ranging from thirty-seven million to fifty-four million shares, which is somewhat variable compared to average trading volumes.
Recently, Pfizer provided its full-year twenty-twenty-five guidance, anticipating revenue between sixty-one billion and sixty-four billion dollars. The company also expects adjusted diluted earnings per share to range from two dollars and eighty cents to three dollars. This guidance reflects operational growth of ten to eighteen percent from the midpoint of twenty-twenty-four's baseline, excluding non-recurring items.
In terms of recent news, Pfizer has been focusing on cost savings and operational improvements. The company achieved a goal of four billion dollars in net cost savings through twenty-twenty-four and expects an additional five hundred million dollars in savings in twenty-twenty-five. Pfizer's strong product lineup, including vital pharmaceuticals and promising new treatments and vaccines, supports a cautiously optimistic outlook for its stock.
Analysts generally have a positive view of Pfizer's stock, though they note the industry's sensitivity to regulatory shifts and competitive dynamics. The stock price is expected to potentially reach thirty dollars by the end of twenty-twenty-four, reflecting annual growth of four percent. However, short-term technical indicators suggest a bearish trend, with resistance at thirty dollars and support at twenty-five dollars and seventy cents. Overall, Pfizer remains a key player in the pharmaceutical sector with a diversified portfolio and strong financial positioning.
For more http://www.quietplease.ai
Stock up on these deals
https://amzn.to/3QFpYIX
Recently, Pfizer provided its full-year twenty-twenty-five guidance, anticipating revenue between sixty-one billion and sixty-four billion dollars. The company also expects adjusted diluted earnings per share to range from two dollars and eighty cents to three dollars. This guidance reflects operational growth of ten to eighteen percent from the midpoint of twenty-twenty-four's baseline, excluding non-recurring items.
In terms of recent news, Pfizer has been focusing on cost savings and operational improvements. The company achieved a goal of four billion dollars in net cost savings through twenty-twenty-four and expects an additional five hundred million dollars in savings in twenty-twenty-five. Pfizer's strong product lineup, including vital pharmaceuticals and promising new treatments and vaccines, supports a cautiously optimistic outlook for its stock.
Analysts generally have a positive view of Pfizer's stock, though they note the industry's sensitivity to regulatory shifts and competitive dynamics. The stock price is expected to potentially reach thirty dollars by the end of twenty-twenty-four, reflecting annual growth of four percent. However, short-term technical indicators suggest a bearish trend, with resistance at thirty dollars and support at twenty-five dollars and seventy cents. Overall, Pfizer remains a key player in the pharmaceutical sector with a diversified portfolio and strong financial positioning.
For more http://www.quietplease.ai
Stock up on these deals
https://amzn.to/3QFpYIX